Since the tumor-promoting role of Wnt/β-catenin and MAPK pathway activities is well established [52,53], chemerin might mediate tumor inhibition by reducing Wnt/β-catenin and MAPK pathway activity in adrenocortical carcinoma and, potentially, other cancer types. This evidence concerns the gene RARRES2 and adrenal cortex carcinoma.